HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EEOC v. Dial

This article was originally published in The Rose Sheet

Executive Summary

Sexual harassment trial moves forward after Chicago Court of Appeals rejects Dial's interim appeal on a motion of summary judgement Feb. 12. Lawsuit filed in May 1999 by Equal Employment Opportunity Commission alleges approximately 90 female workers at Dial's Aurora, Ill. soap manufacturing facility were exposed to verbal abuse, pornography and assault. Trial date is not yet set, according to EEOC. Chicago Federal Court denied Dial's motion of summary judgment in August (1"The Rose Sheet" Aug. 27, 2001, In Brief)...

You may also be interested in...



EEOC v. Dial

Sexual harassment case against Dial will proceed after Chicago federal court denies company's motion for summary judgement Aug. 9. Lawsuit filed in May 1999 by Equal Employment Opportunity Commission alleges approximately 90 female workers at Dial's Aurora, Ill. manufacturing facility were exposed to verbal abuse, pornography and assault while the company's response was "malicious, reckless and ineffective." Dial's liability in the case could exceed $25 mil., according to EEOC. Dial maintains, "There is no finding in this decision that Dial violated the law in any manner"

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel